Studie - Proteinuria – Pipeline Review, H1 2012

Proteinuria — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Proteinuria - Pipeline Review, H1 2012', provides an overview of the Proteinuria therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Proteinuria. 'Proteinuria - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Proteinuria.
- A review of the Proteinuria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Proteinuria pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Proteinuria.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Proteinuria pipeline depth and focus of Proteinuria therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Proteinuria Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Proteinuria 7

Proteinuria Therapeutics under Development by Companies 9

Proteinuria Therapeutics under Investigation by Universities/Institutes 10

Late Stage Products 12

Comparative Analysis 12

Mid Clinical Stage Products 13

Comparative Analysis 13

Early Clinical Stage Products 14

Comparative Analysis 14

Proteinuria Therapeutics — Products under Development by Companies 15

Proteinuria Therapeutics — Products under Investigation by Universities/Institutes 16

Companies Involved in Proteinuria Therapeutics Development 17

Evolva SA 17

Symphony Evolution, Inc. 18

InVasc Therapeutics, Inc. 19

Proteinuria — Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Combination Products 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

EV-077 - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Mycophenolate Mofetil + Prednisolone - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Pentoxifylline + Enalapril + Losartan - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

XL 784 - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Imidapril - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Adalimumab - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Pioglitazone - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

INV-141 - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Rituximab - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Pioglitazone - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Proteinuria Therapeutics — Drug Profile Updates 40

Proteinuria Therapeutics - Dormant Products 42

Proteinuria — Product Development Milestones 43

Featured News & Press Releases 43

Dec 16, 2010: Evolva Begins Multiple Ascending Dose Study With EV-077 43

Jan 03, 2008: GSK Does Not Option XL784 for Further Development 43

Nov 02, 2007: Phase II Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 44

Mar 27, 2006: Exelixis Initiates Phase II Clinical Program for XL784 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 47

Disclaimer 47





List of Tables

Number of Products Under Development for Proteinuria, H1 2012 7

Products under Development for Proteinuria — Comparative Analysis, H1 2012 8

Number of Products under Development by Companies, H1 2012 9

Number of Products under Investigation by Universities/Institutes, H1 2012 11

Comparative Analysis by Late Stage Development, H1 2012 12

Comparative Analysis by Mid Clinical Stage Development, H1 2012 13

Comparative Analysis by Early Clinical Stage Development, H1 2012 14

Products under Development by Companies, H1 2012 15

Products under Investigation by Universities/Institutes, H1 2012 16

Evolva SA, H1 2012 17

Symphony Evolution, Inc., H1 2012 18

InVasc Therapeutics, Inc., H1 2012 19

Assessment by Monotherapy Products, H1 2012 20

Assessment by Combination Products, H1 2012 21

Assessment by Stage and Route of Administration, H1 2012 23

Assessment by Stage and Molecule Type, H1 2012 25

Proteinuria Therapeutics — Drug Profile Updates 40

Proteinuria Therapeutics — Dormant Products 42





List of Figures

Number of Products under Development for Proteinuria, H1 2012 7

Products under Development for Proteinuria — Comparative Analysis, H1 2012 8

Products under Development by Companies, H1 2012 9

Products under Investigation by Universities/Institutes, H1 2012 10

Late Stage Products, H1 2012 12

Mid Clinical Stage Products, H1 2012 13

Early Clinical Stage Products, H1 2012 14

Assessment by Monotherapy Products, H1 2012 20

Assessment by Combination Products, H1 2012 21

Assessment by Route of Administration, H1 2012 22

Assessment by Stage and Route of Administration, H1 2012 23

Assessment by Molecule Type, H1 2012 24

Assessment by Stage and Molecule Type, H1 2012 25

• Growth Hormone Deficiency – Pipeline Review, H1 2013
• Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
• Growth Disorders – Pipeline Review, H1 2013
• Kidney Fibrosis – Pipeline Review, H1 2013
• Urinary Incontinence – Pipeline Review, H1 2013
• Global Endocrinology Drugs Market 2012-2016
• Inguinal Hernia Global Clinical Trials Review, H1, 2013
• End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
• Microalbuminuria – Pipeline Review, H2 2012
• Nocturia – Pipeline Review, H2 2012
• Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
• Hypoparathyroidism – Pipeline Review, H2 2012
• Proteinuria – Pipeline Review, H2 2012
• Thyroid Gland Disorders – Pipeline Review, H2 2012
• Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
• Hypothyroidism Global Clinical Trials Review, H2, 2012
• Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
• Other Genito Urinary Disorders – Pipeline Review, H2 2012
• Urinary Retention Global Clinical Trials Review, H2, 2012
• Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012